Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 19 of 19 results for fingolimod

  1. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA656

  2. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  3. First oral therapy for MS approved by NICE

    Patients with relapsing remitting multiple sclerosis can now be offered a pill that helps reduce the number of relapses, says NICE.

    News
    Published
    25 April 2012

  4. Exploring the impact of NICE technology appraisals

    As NICE publishes its 300th technology appraisal, we look back at the impact they have had on patient care.

    News
    Published
    27 November 2013